Research programme: neuroinflammation targeting agents - ShangPharma Innovation/SRI International
Latest Information Update: 13 Oct 2017
Price : *
At a glance
- Originator ShangPharma; SRI International
- Mechanism of Action Enzyme inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Alzheimer's disease; Neurodegenerative disorders
Most Recent Events
- 09 Oct 2017 Research programme: neuroinflammation targeting agents - ShangPharma Innovation/SRI International is available for licensing as of 09 Oct 2017.
- 09 Oct 2017 ShangPharma and SRI International enter into a collaboration agreement to develop neuroinflmmation targeting compounds
- 09 Oct 2017 Early research in Neurodegenerative disorders and Alzheimer's disease in China (unspecified route)